Growing investments in healthcare infrastructure and advancements in medical research facilities are driving the expansion of cardiac valve repair devices in the Middle East and Africa (MEA) region. Furthermore, factors such as an ageing population, increased life expectancy, and heightened awareness among both patients and healthcare professionals about available treatment options are fueling demand for these devices. Given these developments, the MEA cardiac valve repair devices market is poised for substantial growth in the coming years, according to GlobalData, a leading data and analytics company.
According to GlobalData’s latest models, mitral valve annuloplasty devices will see the strongest growth in the region, with a compound annual growth rate exceeding 8% from 2024 to 2034.
Go deeper with GlobalData
Valve repair is generally preferred over replacement for eligible patients due to its association with lower short-term and long-term mortality and morbidity rates. The growing prevalence of mitral valve regurgitation and valvular stenosis further supports the demand for repair devices. Additionally, the cost of valve repair devices and procedures is lower than alternative treatments, making them a viable option for healthcare providers and patients.
However, challenges exist with the popularity of transcatheter mitral valve repair and transcatheter aortic valve replacement devices. The increased adoption of these devices could lead to disruptions due to their availability.
Currently, Medtronic holds the largest market share in the MEA region for cardiac valve repair devices, followed by Edwards Lifesciences. As the market evolves, continued investments in research and innovation will be crucial in shaping the competitive landscape in the MEA.
South Africa mirrors these broader regional trends, standing among the largest healthcare investors in Africa. As the country’s ageing population continues to grow, it is expected to see increasing adoption of valve repair treatments.
